Solid Biosciences Inc. (SLDB)

Solid Biosciences to Present at Upcoming Scientific and Patient Advocacy Conferences

CAMBRIDGE, Mass., June 23, 2022 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that the Company will participate in the following upcoming scientific and patient advocacy conferences: PPMD 2022 Annual Conference – June 23-26, 2022, Scottsdale, AZCarl Morris, Ph.D., Chief Scientific Officer at Solid Biosciences, will participate in the Gene Therapy Approaches t

• 
  Sarepta stock plunges after FDA puts study on hold

  MarketWatch
• 
  PTC Stock Has Gained 41% This Week Alone, And It's Still Sprinting

  Investor's Business Daily

Solid Biosciences Reports Inducement Grant to New Senior Vice President, Quality

CAMBRIDGE, Mass., June 02, 2022 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced the grant of inducement awards to its newly appointed Senior Vice President, Quality, Mark Tucker, PhD. The grant was approved by a majority of the independent directors of the Company on April 25, 2022 as an inducement material to Dr. Tucker entering into employment with the Compan

Solid Biosciences to Participate at the Jefferies Healthcare Conference

CAMBRIDGE, Mass., June 02, 2022 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Ilan Ganot, Chief Executive Officer, Co-Founder and President, and Carl Morris, PhD, Chief Scientific Officer, will participate in a fireside chat at the Jefferies Healthcare Conference on Friday, June 10, 2022 at 10:30 a.m. ET. A live webcast will be available on the Company’s